Groundbreaking Study Shows Promise of iNKT Cell Therapy in Treating ARDS
Groundbreaking phase 1/2 clinical trial reveals the potential of iNKT cell therapy in treating moderate-severe ARDS caused by SARS-2 virus. AgenT-797 shows promise in rescuing exhausted T cells and activating innate and adaptive immunity without toxicities. Study points to iNKT cells’ anti-inflammatory response, survival benefits, and potential for treating infections and cancer.
Study: Maternal COVID-19 vaccination may reduce neonatal respiratory distress
Recent research published in Nature Communications has shed light on the potential respiratory distress experienced by uninfected neonates exposed to SARS-CoV-2. The study, titled ‘Respiratory distress in SARS-CoV-2 exposed uninfected neonates followed in the COVID Outcomes in Mother-Infant Pairs (COMP)…